Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ANVS Annovis Bio, Inc.

Trading 05-19 10:57:00 EDT

1.99

-0.06

-2.93%

High2.04	Low1.96	Vol218.66K
Open2.04	D1 Closing2.05	Amplitude4.15%
Mkt Cap68.72M	Tradable Cap60.57M	Total Shares34.53M
T/O433.61K	T/O Rate0.72%	Tradable Shares30.44M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ANVS","market":"US","secType":"STK","nameCN":"Annovis Bio, Inc.","latestPrice":1.99,"timestamp":1779202616464,"preClose":2.05,"halted":0,"volume":218655,"delay":0,"changeRate":-0.02926829268292675,"floatShares":30437600,"shares":34532400,"eps":-1.767283,"marketStatus":"Trading","change":-0.06,"latestTime":"05-19 10:57:00 EDT","open":2.04,"high":2.04,"low":1.955,"amount":433611.7786575,"amplitude":0.041463,"askPrice":2,"askSize":300,"bidPrice":1.99,"bidSize":262,"shortable":3,"etf":0,"ttmEps":-1.767283,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1779220800000},"marketStatusCode":2,"adr":0,"listingDate":1580274000000,"exchange":"NYSE","adjPreClose":2.05,"preHourTrading":{"tag":"盘前","latestPrice":2.0204,"preClose":2.05,"latestTime":"09:04 EDT","volume":835,"amount":1694.1035275,"timestamp":1779195863407,"change":-0.0296,"changeRate":-0.014439,"amplitude":0.077854},"postHourTrading":{"tag":"盘后","latestPrice":2.05,"preClose":2.05,"latestTime":"19:12 EDT","volume":62,"amount":127.87,"timestamp":1779145927340,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.312285,"impliedVol":2.3709,"impliedVolPercentile":0.8725},"requestUrl":"/m/hq/s/ANVS","defaultTab":"news","newsList":[{"id":"2635080190","title":"Annovis Bio Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635080190","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635080190?lang=en_us&edition=fundamental","pubTime":"2026-05-15 21:41","pubTimestamp":1778852460,"startTime":"0","endTime":"0","summary":"Annovis Bio Inc reports results for the quarter ended December 31 - Earnings SummaryAnnovis Bio Inc ANVS.N reported a quarterly adjusted loss of 63 cents per share for the quarter ended December 31, l","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S1HK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089470","title":"Annovis Bio Q1 EPS $(0.63) Misses $(0.40) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089470","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635089470?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:38","pubTimestamp":1778845135,"startTime":"0","endTime":"0","summary":"Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.40) by 61.54 percent. This is a 96.88 percent decrease over losses of $(0.32) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52592507/annovis-bio-q1-eps-0-63-misses-0-40-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635947089","title":"Annovis Bio Inc - Cash and Cash Equivalents $14.2 Mln as of March 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635947089","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635947089?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:30","pubTimestamp":1778844601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA1JRDML:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089930","title":"Press Release: Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089930","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635089930?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:30","pubTimestamp":1778844600,"startTime":"0","endTime":"0","summary":"-- Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in. -- PD open-label extension  study: 40% of patients enrolled; full. -- New Drug Application  for buntanetap as a symptomatic treatment for. AD is expected in early 2027 and as a potential disease-modifying. \"We saw strong momentum across both our AD and PD programs in the first quarter,\" said Maria Maccecchini, Ph.D., President and CEO of Annovis. \"Our Phase 3 AD clinical trial achieved significant enrollment growth, keeping us firmly on track to complete randomization of patients in summer 2026 and deliver first top-line results in early 2027. Simultaneously, we launched a PD OLE study and have been encouraged by the robust interest from both returning and new patients. This year is pivotal: we expect to generate substantive clinical data across both indications that will anchor our regulatory path toward an NDA submission for buntanetap.\". -- Screening: On May 15, 2026, Annovis closed enrollment to new partici","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DBS","PD","AD","LU1169589451.USD","ANVS","BK4023","BK4139","LU1169590202.USD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633541554","title":"Annovis Bio Inc  expected to post a loss of 39 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633541554","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633541554?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:38","pubTimestamp":1778247497,"startTime":"0","endTime":"0","summary":"Annovis Bio Inc  expected to post a loss of39cents a share - Earnings Preview Annovis Bio Inc ANVS.N, ANVS.K is expected to  show no change in quarterly revenue when it reports  results on May 11 (est","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1IK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633308149","title":"Annovis Bio CEO presents multi-protein Alzheimer’s model at Fierce Biotech Week 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633308149","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633308149?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:32","pubTimestamp":1778153548,"startTime":"0","endTime":"0","summary":"Annovis to present at Fierce Biotech Week 2026 in Boston on May 13, 2026.CEO Maria Maccecchini scheduled to discuss a multi-protein model of Alzheimer’s disease, framing it as a rationale for the company’s buntanetap development program.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL5CNqj1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2095319765.USD","BK4585","IE00BN0W2W23.USD","IE00BGHQF748.EUR","LU2210149790.SGD","SG9999014005.SGD","BK4588","LU2210150020.SGD","ANVS","LU0314104364.USD","NDAQ","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","SG9999014013.SGD","BK4139","BK4112","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632662892","title":"Annovis Bio announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2632662892","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632662892?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:28","pubTimestamp":1777584508,"startTime":"0","endTime":"0","summary":"Annovis Bio annual shareholder meeting scheduled for June 17, 2026, to be held virtually.Shareholders set to vote on election of five directors.Ballot includes ratification of Ernst & Young as independent auditor for fiscal 2026.Items also include amendment to 2019 Equity Incentive Plan to raise share reserve to 5,500,000 shares.Advisory votes planned on executive compensation, including preferred frequency of future say-on-pay votes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 30, 2026, and is solely responsible fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDLb98gQ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630301145","title":"Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2630301145","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630301145?lang=en_us&edition=fundamental","pubTime":"2026-04-28 20:00","pubTimestamp":1777377600,"startTime":"0","endTime":"0","summary":"Buntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegenerationBuntanetap was safe and well-tol","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/28/3282572/0/en/Annovis-Publishes-Phase-2-3-Alzheimer-s-Trial-Results-in-Nature-Portfolio.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","ANVS","LU1169589451.USD","AD","BK4139","PD","LU1169590202.USD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627644032","title":"Annovis Bio Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2627644032","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627644032?lang=en_us&edition=fundamental","pubTime":"2026-04-14 23:13","pubTimestamp":1776179580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANVS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 14, 2026 11:13 ET (15:13 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626359190","title":"Annovis Bio raises USD 10 million in underwritten public offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2626359190","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626359190?lang=en_us&edition=fundamental","pubTime":"2026-04-10 20:31","pubTimestamp":1775824278,"startTime":"0","endTime":"0","summary":"Annovis Bio closed an underwritten public offering that raised about USD 10 million in gross proceeds.Cash runway now extends through Q2 2027, including existing cash and a USD 1.5 million board-chair investment.Funding supports Phase 3 Alzheimer’s program for buntanetap, with 6-month symptomatic data expected in Q1 2027.Phase 3 Alzheimer’s trial is 75% enrolled; Parkinson’s open-label extension study is 28% enrolled.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL3PMj2H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4112","LU2095319765.USD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","NDAQ","LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014021.USD","LU2210149790.SGD","SG9999014013.SGD","BK4139","SG9999014005.SGD","IE00BN0W2V16.EUR","SG9999014039.USD","ANVS","BK4588","IE00BKPKM429.USD","LU0314104364.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626191834","title":"Annovis Bio Prices Registered Direct Offering to Fund Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2626191834","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626191834?lang=en_us&edition=fundamental","pubTime":"2026-04-10 18:38","pubTimestamp":1775817518,"startTime":"0","endTime":"0","summary":"An announcement from Annovis Bio ( ($ANVS) ) is now available. On April 9, 2026, Annovis Bio priced an underwritten registered direct offering of 5...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/annovis-bio-prices-registered-direct-offering-to-fund-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/annovis-bio-prices-registered-direct-offering-to-fund-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626231134","title":"BUZZ-U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman","url":"https://stock-news.laohu8.com/highlight/detail?id=2626231134","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626231134?lang=en_us&edition=fundamental","pubTime":"2026-04-10 01:51","pubTimestamp":1775757106,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-FormanWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call new","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a6220b127d3bbee7041552a4a4e77ac3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nL6N40S0MV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMZN","MRVU","MVLL","APLD","GLMD","TSLQ","CAT","CRSH","FBRX","AZYY","TSLA","HRL","CRWG","KYMR","STZ","VNDA","RELL","ANVS","CCCC","NOC","NRGV","STAA","IDYA","TEMT","BLSG","OXY","TSLR","TSLS","WW","ADSK","CORD","CRWU","BLSX","NUAI","TSLP","MRVL","TSLG","TSLO","TEM","GDRX","FDX","WSR","CG","TSL","TSLL","BLSH","SMPL","TSLI","CRWV","NOW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626827861","title":"BRIEF-Annovis Announces $10 Million Underwritten Offering Of Common Stock And Accompanying Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2626827861","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626827861?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:46","pubTimestamp":1775738804,"startTime":"0","endTime":"0","summary":"BRIEF-Annovis Announces $10 Million Underwritten Offering Of Common Stock And Accompanying WarrantsApril 9 (Reuters) - Annovis Bio Inc ANVS.N:ANNOVIS ANNOUNCES $10 MILLION UNDERWRITTEN OFFERING OF COM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUA5TYFTG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626218251","title":"Annovis Bio prices USD 10 million stock offering with warrants at USD 1.9 unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2626218251","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626218251?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:33","pubTimestamp":1775738039,"startTime":"0","endTime":"0","summary":"Annovis Bio priced an underwritten follow-on offering of 5,263,156 common shares with warrants to buy up to 5,263,156 additional shares.Offering price set at USD 1.9 for each share-warrant package.Warrants carry an exercise price of USD 2.5 per share, become exercisable six months after issuance, expire 5.5 years from issuance.Gross proceeds expected at about USD 10 million, excluding any warrant exercise proceeds.Net proceeds earmarked for Phase 3 development of buntanetap in Alzheimer’s disease, working capital, general corporate purposes.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL6t0Gss:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","LU2210149790.SGD","LU2210150020.SGD","LU2095319765.USD","ANVS","IE00B3QW5Z07.USD","NDAQ","SG9999014039.USD","BK4588","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014021.USD","SG9999014005.SGD","IE00BKPKM429.USD","LU0314104364.USD","SG9999014013.SGD","BK4112","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626182392","title":"Annovis Bio Inc - Combined Offering Price per Share and Warrant Is $1.90","url":"https://stock-news.laohu8.com/highlight/detail?id=2626182392","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626182392?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:30","pubTimestamp":1775737803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUA5TYFTG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626874261","title":"Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2626874261","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626874261?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:30","pubTimestamp":1775737800,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., April  09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/09/3270958/0/en/Annovis-Announces-10-Million-Underwritten-Offering-of-Common-Stock-and-Accompanying-Warrants.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","BK4023","LU1169590202.USD","BK4132","LU1169589451.USD","BK4139","ANVS","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624693140","title":"Top Insider Makes Bold Multi-Million Dollar Move Into Annovis Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2624693140","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624693140?lang=en_us&edition=fundamental","pubTime":"2026-04-04 10:02","pubTimestamp":1775268179,"startTime":"0","endTime":"0","summary":"New insider activity at Annovis Bio ( ($ANVS) ) has taken place on April 3, 2026. Director Michael B. Hoffman has significantly increased his stake...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-insider-makes-bold-multi-million-dollar-move-into-annovis-bio-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-insider-makes-bold-multi-million-dollar-move-into-annovis-bio-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624664066","title":"Annovis Bio director Michael B. Hoffman buys $1.5 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2624664066","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624664066?lang=en_us&edition=fundamental","pubTime":"2026-04-04 05:07","pubTimestamp":1775250427,"startTime":"0","endTime":"0","summary":"Annovis Bio director Michael B. Hoffman bought 713,800 common shares at USD 2.1 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL9RRyD0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Annovis Bio director Michael B. Hoffman buys $1.5 million common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624505517","title":"Annovis Bio wins U.S. patent for buntanetap to treat brain infection-related injuries","url":"https://stock-news.laohu8.com/highlight/detail?id=2624505517","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624505517?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:30","pubTimestamp":1775129428,"startTime":"0","endTime":"0","summary":"Annovis Bio secured U.S. Patent No. 12,582,632 B2 covering use of buntanetap to prevent or treat neurological injuries linked to brain infections.Patent claims include preventive use in at-risk healthy individuals.Claims also cover treatment intended to reverse neurological damage in infected patients.Buntanetap is Annovis’ Phase 3 oral drug candidate for Alzheimer’s disease and Parkinson’s disease.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL3rJNsW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS","IE00BKPKM429.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","BK4585","SG9999014021.USD","IE00BN0W2W23.USD","NDAQ","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BGHQF748.EUR","LU2210149790.SGD","SG9999014005.SGD","LU2210150020.SGD","IE00BN0W2T93.GBP","LU0314104364.USD","BK4588","SG9999014039.USD","BK4112","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623584887","title":"Annovis Publishes Historical Review of Buntanetap in The Scientist","url":"https://stock-news.laohu8.com/highlight/detail?id=2623584887","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623584887?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:00","pubTimestamp":1774958400,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., March  31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therap","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/31/3265424/0/en/Annovis-Publishes-Historical-Review-of-Buntanetap-in-The-Scientist.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","ANVS","AD","LU1169589451.USD","LU1169590202.USD","BK4023","PD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.annovisbio.com","stockEarnings":[{"period":"1week","weight":-0.1423},{"period":"1month","weight":0.0963},{"period":"3month","weight":-0.1387},{"period":"6month","weight":-0.3935},{"period":"1year","weight":0.1453},{"period":"ytd","weight":-0.4075}],"compareEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":0.0401},{"period":"3month","weight":0.0817},{"period":"6month","weight":0.1147},{"period":"1year","weight":0.2431},{"period":"ytd","weight":0.0832}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.040659},{"month":2,"riseRate":0.285714,"avgChangeRate":0.058949},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.056117},{"month":4,"riseRate":0.142857,"avgChangeRate":-0.132244},{"month":5,"riseRate":0.714286,"avgChangeRate":0.26508},{"month":6,"riseRate":0.5,"avgChangeRate":0.167707},{"month":7,"riseRate":0.666667,"avgChangeRate":0.098191},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.070358},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.058484},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.073043},{"month":11,"riseRate":0.666667,"avgChangeRate":0.26823},{"month":12,"riseRate":0.333333,"avgChangeRate":0.124011}],"exchange":"NYSE","name":"Annovis Bio, Inc.","nameEN":"Annovis Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Annovis Bio, Inc.,ANVS,Annovis Bio, Inc.股票,Annovis Bio, Inc.股票老虎,Annovis Bio, Inc.股票老虎国际,Annovis Bio, Inc.行情,Annovis Bio, Inc.股票行情,Annovis Bio, Inc.股价,Annovis Bio, Inc.股市,Annovis Bio, Inc.股票价格,Annovis Bio, Inc.股票交易,Annovis Bio, Inc.股票购买,Annovis Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction